teh FDA did not even look at it because Orion didn't submit any data.
You're losing any credibility fast (if you ever had any).
The FDA did not reject this drug. It did not even review this drug.
But this drug will be given to only surgery patients pre-op to help with surgery to and expedite recovery. Those patients are already very high risk. In their case, the benefit will outweigh the risk. This drug, as far as I know, is not given to non-surgery patients. It's not a drug you take daily for your life to treat a chronic condition. It is used before an dafter heart surgery to encourage healing. It encourages the heart to contract.
My hunch is that the FDA will approve, but for only surgery patients. It will be for inpatient use only.
what makes you think they need funding? they are conducting trials, but do they need more funding? Do you know this for a fact?
but it works in Europe It is approved in Europe. It is sold in Europe.
Why would a multi-billion dollar company bother itself with a drug that might bring in only 200 million a year? Now, imagine that OBXT brought in that much.
Orion has Europe. They probably didn't care about America. Maybe their ambition is modest.
Everything you have said is circumstantial.Everything I have said is circumstantial.
My hunch is OBXT will hit a 100 million market cap before anybody starts to think to question anything. I'm just going to ride it up and bail before the FDA review.
It failed in Abbott's trials YET has been good enough to be sold in Europe, which means Abbott simply gave up to early or didn't think it was worth it. From what I read, it worked in Abbott's study, but it was not massively superior to placebo. But it did work. It did not fail. It just didn't blow placebo away. If I am correct, Abbott was a multi billion dollar company at the time and didn't need an iffy small revenue gainer. So, they sold it back to Orion, who tried to get it approvd in the US using old data from European trails. The FDA said "no; you need new data for us." Orion said "nevermind. Why bother? we'll just do Europe."
It was never rejected by the FDA. That's misinformation. The FDA would not look at old data. No new trials were run. That means there was no drug application submitted. IT was not rejected because it was reviewed.
It has been approved in Europe.
Fair enough, but that's a minor matter. I'm more interested in Wittgenstein and TS Eliot.
Beautiful women don't care that much about grammar, and those are the people I spend most of my time communicating with online. I read to keep my brain from going dead.
In general, colons and semi-colons confuse people. If you want to get laid, it's best to eschew grammar that confuses thin women.
My point was that I have no background in finance.
ARNA and,VVUS. But both have fallen since FDA approval. However, I don't hold through the FDA review date. I sell before the review.
I'm an English professor. I have no background in finance.
Orion tried this ten years ago, I believe. The FDA didn't accept it. The reason this has not been approved for the US and Canada is that it has never been reviewed by the FDA. Abbott's trials were stopped because it didn't seem effective enough. Orion refused to run new trails for the FDA. Apparently, the drug works, even through Abbott discontinued their trails. The drug is used in parts of Europe.
As far as I know, this drug has never been examined by the FDA. So, it has never been rejected by the FDA.
From my very limited research, Phyxius is not a company the develops drugs. It looks like they both market drugs they buy and also supervise other small companies on bringing drugs to the market. Phyxius' website (from my quick reading of it) makes it sound like Phyxius is more in the business of advising OTHER drug companies. They don't seem to have a pipeline of their own. My best guess at this point s that they are always the middle man. They buy a property and then sell it maybe for a stake in that company working on the belief that the product will make a profit. In order for this to work, they need a company that has the infrastructure to run trials but so low a share price that the stock they get in return (n this case 3.5 million shares) won't drop much. If they sell it to a high flying company, they may lose value on the deal if that share price drops. But as far as a I can tell, OXBT shares were at support.
In my theory, Phyxius needs to find a company with
a) no active piplein of their own (OXBT's main drug candidate is suspended by the FDA)
b) has the strcuture to develop and market a drug (OXBT has that).
c) has a share price near the very bottom of support (check).
That's how I see it, but I'm new to this.
600 million market. most companies expecting an FDA review rise to 1/2 expected market by the time of the review. This happens with many drug companies I've watched. My number is based on a 1/4 rise by the time of the FDA review, which is more conservative.
My numbers are based ONLY on expected market (600 million) and the trend for companies to rise to 1/2 the value of expected sales by the date of an FDA decision. Sometimes it's only 1/4 expected value of sales, which would be a 150 million market cap.
29 is based on a market cap of 150m.
I live in NYC. A studio apartment in my building sells for 550k.
how do you figure 17? If the market is 600, and all goes right, the company should achieve a 600 market cap, which is 40 times what it is now. 15 million goes into 600 million 40 times. 40 times 3.2 = 128.
This is barring dissolution.